INDmoney
Dr Lal Share Price
₹1405.80
as on
🔔 Rating Alert
Morgan Stanley trims target price for Dr Lal PathLabs to ₹1,765 while maintaining an Overweight rating; CLSA retains Outperform rating with a target price of ₹1,660.
Dr Lal Stock Performance
as on February 3, 2026 at 4:01 pm IST
Day's Low
Day's High
₹1,390.00₹1,443.80
1.12%
Downside
2.70%
Upside
52 Week's Low
52 Week's High
₹1,146.78₹1,770.0018.43%
Downside
25.91%
Upside
Dr Lal share price movements today
- Previous Close
- ₹1,417.70
- Open
- ₹1,443.80
- Volume
- 2.91L
- Upper Circuit
- ₹1,701.20
- Lower Circuit
- ₹1,134.20
- Day's Low - High
- ₹1,390.00 - ₹1,443.80
- 52 Week Low - High
- ₹1,146.78 - ₹1,770.00
Dr Lal Historical Returns
- 1 Month Return
- -5.62 %
- 3 Month Return
- -12.89 %
- 1 Year Return
- + 0.64 %
- 3 Year Return
- + 50.41 %
- 5 Year Return
- + 19.51 %
Dr Lal Fundamentals
as on February 3, 2026 at 4:01 pm IST
Market Cap
₹23,754.28 Cr
Return on Equity (ROE)
24.65
PE Ratio (TTM)
44.76
Return on capital employed (ROCE)
29.14
Industry PE ratio
45.62
Beta (LTM)
0.37
P/B Ratio
9.71
Dividend Yield
0.97
PEG Ratio
6.73
Quarterly Earnings Growth YOY
-6.83
EPS (TTM)
29.445
Sector
Healthcare
Book Value
129.96
Technical Analysis
Bearish
View Technical Analysis
Dr Lal Stock Valuation
as on February 3, 2026 at 4:01 pm IST
Dr Lal in the last 5 years
Lowest (37.51x)
November 16, 2018
Today (44.76x)
February 2, 2026
Industry (45.62x)
February 2, 2026
Highest (95.62x)
November 5, 2020
Today’s Price to Earnings Ratio: 44.76x
Dr Lal Pathlabs Ltd vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Dr Lal with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 23,754.28 | 3.9% | 0.54 | 492 | 2,461 | |
| HOLD | 51,499.62 | 35.84% | 0.71 | 354 | 5,553 | |
| HOLD | 66,017.81 | 17.54% | 0.59 | 2,216 | 12,964 | |
| BUY | 9,897.12 | 11.02% | 0.65 | 143 | 704 | |
| BUY | 6,302.01 | 6.39% | 0.53 | 90 | 687 |
Analyst Recommendation on Dr Lal Stock
Based on 26 analysts
73.08%
Buy
3.85%
Hold
23.08%
Sell
Based on 26 analysts, 73.08% of analysts recommend a 'BUY' rating for Dr Lal. Average target price of ₹1680.85
Source: S&P Global Market Intelligence
Dr Lal Share Price Target
Get share price movements and forecasts by analysts on Dr Lal.
What analysts predicted
18.56%UPSIDE
Target Price
₹1680.85
Current Price
₹1405.8
Analyzed by
26 Analysts
High
₹2090
Target
₹1680.85
Low
₹1097
Dr Lal target price ₹1680.85, a slight upside of 18.56% compared to current price of ₹1405.8. According to 26 analysts rating.
Source: S&P Global Market Intelligence
Dr Lal Stock’s Investor Sentiment and Interest
Search interest for Dr Lal Pathlabs Ltd Stock has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Dr Lal Pathlabs Ltd Quarterly Profit & Loss
Figures in Rupees Crores
Dr Lal Pathlabs Ltd Annual Profit & Loss
Figures in Rupees Crores
Dr Lal Pathlabs Ltd Cash Flow
Figures in Rupees Crores
Dr Lal Stock Shareholding Pattern
Numbers in percentages
Mutual Funds that own Dr Lal Stock
Check out the Mutual Funds with significant holdings in Dr Lal.
Funds | Holdings | Shares Held | |
|---|---|---|---|
 HDFC Flexi Cap Fund -Direct Plan - Growth Option | 0.62% | 4000000 | |
 UTI Flexi Cap Fund - Growth Option - Direct | 1.43% | 2401252 | |
 Aditya Birla Sun Life Flexi Cap Fund Direct Plan Growth | 0.99% | 1668560 | |
 Nippon India Multi Cap Fund - Direct Plan - Growth | 0.38% | 1302307 | |
 SBI Large & Midcap Fund Direct Growth | 0.51% | 1300000 |
Dr Lal Corporate Actions
View detailed summary of the earnings and dividend history of Dr Lal.
Dr Lal Pathlabs Ltd Earnings Results
Dr Lal Pathlabs Ltd’s net profit fell -6.41% since last year same period to ₹90.50Cr in the Q3 2025-2026. On a quarterly growth basis, Dr Lal Pathlabs Ltd has generated -39.91% fall in its net profits since last 3-months.
Read More about Earnings ResultsDr Lal Pathlabs Ltd Dividends January,2026
In the quarter ending December 2025, Dr Lal Pathlabs Ltd has declared dividend of ₹3.50 per share on 30 Jan 2026 - translating a dividend yield of 2.01%.
Read More about Dividends
Indices Featuring Dr Lal Stock
Check stock indices that include Dr Lal.
Insights on Dr Lal Pathlabs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 15.04% to 15.90% in Sep 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 132.4 Cr → 150.4 Cr (in ₹), with an average increase of 12.0% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 621.8 Cr → 755.4 Cr (in ₹), with an average increase of 6.2% per quarter
- POSITIVE IMPACT
Price Rise
In the last 1 year, LALPATHLAB stock has moved up by 0.6%
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 21.68% to 21.86% in Sep 2025 quarter
NO EFFECTAgainst Peers
In the last 3 years, Fortis Healthcare Ltd has given 202.2% return, outperforming this stock by 151.8%
- NO EFFECT
Against Peers
In the last 1 year, Fortis Healthcare Ltd has given 35.0% return, outperforming this stock by 34.3%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 6.23% to 6.07% in Sep 2025 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 53.79% to 53.22% in Sep 2025 quarter
About Dr Lal Pathlabs Ltd
The company's top products include pathology tests, imaging tests, and preventive health check-ups. Its popular brands include Dr Lal PathLabs, Lal PathLabs, and Lal PathLabs Diagnostics. Dr Lal PathLabs Ltd has over 2000 labs across India, with more than 2000 collection centers, and over 20000 trained professionals. The company is also present in Nepal, Sri Lanka, and Bangladesh.
Dr Lal PathLabs Ltd is committed to providing quality healthcare services and products to its customers. It is ISO 9001:2015 certified and has been accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).
Revenue: ₹659.80Cr as on December 2025 (Q3 FY26)
Net Profit: ₹91.40Cr as on December 2025 (Q3 FY26)
Listing date: 23 Dec, 2015
Chairperson Name: Arvind Lal
| Organisation | Dr Lal Pathlabs Ltd |
| Headquarters | Gurgaon |
| Industry | Healthcare |
| CEO | Arvind Lal |
| E-voting on shares | Click here to vote |
FAQs
What is Dr Lal share price today?
Dr Lal share price today stands at ₹1405.8 as on at the close of the market. Dr Lal share today touched a day high of ₹1443.8 and a low of ₹1390.
What is the 52 week high and 52 week low range for Dr Lal share?
Dr Lal touched a 52 week high of ₹1770 and a 52 week low of ₹1146.78. Dr Lal share price today i.e. is closed at ₹1405.8, which is -20.58% down from its 52 week high and 22.59% up from its 52 week low.
What is Dr Lal's market capitalisation today?
Dr Lal market capitalisation is ₹23,754.28 Cr as on .
How to buy Dr Lal shares?
To buy Dr Lal shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for LALPATHLAB or Dr Lal Pathlabs Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Dr Lal shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is Dr Lal trading volume today?
Dr Lal trading volume is 2.91L as on . This means that 2.91L shares of Dr Lal were bought and sold on the stock market during today's trading session.